Relative Value Partners Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $800K | Buy |
28,589
+12,672
| +80% | +$349K | 0.1% | 168 |
|
|
2024
Q1 | $431K | Sell |
15,917
-3,310
| -17% | -$91.8K | 0.03% | 210 |
|
|
2023
Q4 | $554K | Buy |
19,227
+148
| +0.8% | +$4.47K | 0.03% | 190 |
|
|
2023
Q3 | $633K | Buy |
19,079
+5,754
| +43% | +$203K | 0.04% | 167 |
|
|
2023
Q2 | $489K | Buy |
13,325
+4
| +0% | +$156 | 0.03% | 185 |
|
|
2023
Q1 | $543K | Sell |
13,321
-1,623
| -11% | -$70.1K | 0.04% | 173 |
|
|
2022
Q4 | $766K | Buy |
14,944
+2,855
| +24% | +$137K | 0.05% | 166 |
|
|
2022
Q3 | $529K | Sell |
12,089
-3,706
| -23% | -$180K | 0.04% | 170 |
|
|
2022
Q2 | $778K | Sell |
15,795
-1,382
| -8% | -$70.4K | 0.06% | 134 |
|
|
2022
Q1 | $889K | Buy |
17,177
+6,341
| +59% | +$329K | 0.06% | 145 |
|
|
2021
Q4 | $640K | Hold |
10,836
| – | – | 0.05% | 123 |
|
|
2021
Q3 | $466K | Buy |
10,836
+450
| +4% | +$19.9K | 0.03% | 134 |
|
|
2021
Q2 | $407K | Sell |
10,386
-902
| -8% | -$35.1K | 0.03% | 143 |
|
|
2021
Q1 | $409K | Buy |
11,288
+1,338
| +13% | +$47.5K | 0.04% | 151 |
|
|
2020
Q4 | $366K | Sell |
9,950
-1,644
| -14% | -$60.3K | 0.03% | 156 |
|
|
2020
Q3 | $404K | Buy |
11,594
+4,005
| +53% | +$140K | 0.04% | 128 |
|
|
2020
Q2 | $235K | Hold |
7,589
| – | – | 0.02% | 161 |
|
|
2020
Q1 | $235K | Hold |
7,589
| – | – | 0.03% | 154 |
|
|
2019
Q4 | $282K | Hold |
7,589
| – | – | 0.03% | 141 |
|
|
2019
Q3 | $259K | Buy |
7,589
+527
| +7% | +$19.2K | 0.03% | 137 |
|
|
2019
Q2 | $290K | Sell |
7,062
-946
| -12% | -$37.6K | 0.03% | 132 |
|
|
2019
Q1 | $323K | Buy |
8,008
+1,473
| +23% | +$59K | 0.03% | 132 |
|
|
2018
Q4 | $271K | Hold |
6,535
| – | – | 0.03% | 131 |
|
|
2018
Q3 | $273K | Hold |
6,535
| – | – | 0.03% | 125 |
|
|
2018
Q2 | $225K | Sell |
6,535
-527
| -7% | -$18K | 0.02% | 134 |
|
|
2018
Q1 | $238K | Buy |
7,062
+738
| +12% | +$25.4K | 0.03% | 133 |
|
|
2017
Q4 | $217K | Hold |
6,324
| – | – | 0.02% | 116 |
|
|
2017
Q3 | $214K | Hold |
6,324
| – | – | 0.02% | 108 |
|
|
2017
Q2 | $202K | Sell |
6,324
-1,113
| -15% | -$35.1K | 0.02% | 116 |
|
|
2017
Q1 | $242K | Buy |
7,437
+422
| +6% | +$13.3K | 0.03% | 119 |
|
|
2016
Q4 | $216K | Hold |
7,015
| – | – | 0.03% | 124 |
|
|
2016
Q3 | $225K | Sell |
7,015
-6,641
| -49% | -$222K | 0.03% | 119 |
|
|
2016
Q2 | $456K | Hold |
13,656
| – | – | 0.07% | 87 |
|
|
2016
Q1 | $418K | Buy |
13,656
+481
| +4% | +$13.7K | 0.05% | 96 |
|
|
2015
Q4 | $404K | Hold |
13,175
| – | – | 0.05% | 98 |
|
|
2015
Q3 | $393K | Hold |
13,175
| – | – | 0.05% | 94 |
|
|
2015
Q2 | $419K | Buy |
+13,175
| New | +$429K | 0.05% | 87 |
|
Other funds holding PFE
Relative Value Partners Group's PFE Position: Q2 2024 in Review
Relative Value Partners Group increased its Pfizer (PFE) stake by 80% in Q2 2024, buying an estimated $349K and bringing the position to 28,589 shares worth $800K. The position accounts for 0.1% of the portfolio, ranked #168.
Relative Value Partners Group first reported a position in PFE in Q2 2015 and has held it in 37 quarters since. The position peaked at $889K in Q1 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Relative Value Partners Group held 28,589 shares of Pfizer worth $800K as of Q2 2024.
- Relative Value Partners Group bought 12,672 Pfizer shares in Q2 2024, an estimated $349K.
- Pfizer made up 0.1% of Relative Value Partners Group's portfolio in Q2 2024, its #168 holding.
- Relative Value Partners Group first reported a position in Pfizer in Q2 2015 and has held it in 37 quarters since.
- Relative Value Partners Group's Pfizer position peaked at $889K in Q1 2022.
- 2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.